Results 191 to 200 of about 396,260 (312)
Can combined biomarker testing shape the future of primary care antibiotic prescribing? [PDF]
Llor C, Kjær NK.
europepmc +1 more source
Expert Perspectives: Defining and Managing Progressive Pulmonary Fibrosis in Systemic Sclerosis
Systemic sclerosis–associated interstitial lung disease (SSc‐ILD) is one of the leading causes of morbidity and mortality in SSc, affecting up to three‐quarters of patients. The disease course is highly heterogeneous, ranging from indolent, nonprogressive forms to rapidly progressive pulmonary fibrosis (PPF).
Devis Benfaremo +7 more
wiley +1 more source
Residual inflammatory risk post STEMI: high prevalence despite LDL-C control and association with other secondary prevention targets. [PDF]
Hassan A +9 more
europepmc +1 more source
From Interferon Signature to the Clinical Landscape: Type I Interferonopathies
Objective TypeI interferonopathies are heterogeneous diseases driven by dysregulated type I interferon (IFN‐I) signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. The aim of this study was to characterize the clinical, immunologic, genetic, molecular profiles of patients with suspected ...
Ismail Yaz +13 more
wiley +1 more source
Impact of concomitant fibromyalgia on disease activity assessment and quality of life in Vietnamese patients with rheumatoid arthritis. [PDF]
Thi NT, Thi HD, Thi HV, Thi Phuong TN.
europepmc +1 more source
Objective Axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) are overlapping yet distinct conditions within the SpA spectrum. As divergent immunophenotypes may influence disease course and therapeutic response, we compared immune cell subsets, cytokine profiles, and inflammatory mediators.
Natalie Frede +11 more
wiley +1 more source
Calprotectin as a Diagnostic Marker for Lower Respiratory Tract Infection and Sepsis in the Emergency Department. [PDF]
Wollmer M +4 more
europepmc +1 more source
Objective To assess the pharmacokinetics, effectiveness, safety, and immunogenicity of certolizumab pegol (CZP) in polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods Pediatric Arthritis Study of Certolizumab Pegol (NCT01550003), a multicenter, open‐label study, enrolled patients 2–17 years with active pcJIA and inadequate response ...
Hermine I Brunner +28 more
wiley +1 more source

